Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis

Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
Lisa A ProsserMilton C Weinstein

Abstract

To perform a cost-effectiveness analysis of three immunomodulatory treatments for newly diagnosed nonprimary progressive MS: interferon beta-1a, interferon beta-1b, and glatiramer acetate. We developed a state-transition model to estimate the health effects and costs associated with interferon beta-1a, interferon beta-1b, glatiramer acetate, and no treatment for hypothetical cohorts of men and women with non-primary progressive MS. We used the Expanded Disability Status Scale as the measure of disability and included both relapses and disease progression in the model. We evaluated treatment strategies assuming a 10-year treatment duration using the societal perspective. We elicited preferences for disability and treatment states using standard-gamble questions and modeled the disutility associated with treatment administration and side effects explicitly. Main outcome measures were net gains in quality-adjusted life expectancy and incremental cost-effectiveness ratios in dollars per quality-adjusted life year (QALY) gained. For treatment duration of 10 years for newly diagnosed non-primary progressive MS, interferon beta-1a yielded the largest gain in quality-adjusted life expectancy with an incremental cost-effectiveness ratio...Continue Reading

References

May 1, 1992·Journal of Neurology, Neurosurgery, and Psychiatry·D H MillerG Purdie
Aug 1, 1991·Neurology·A D SadovnickD W Paty
Feb 1, 1993·Brain : a Journal of Neurology·B Runmarker, O Andersen
Dec 1, 1995·The Journal of Neuroscience Nursing : Journal of the American Association of Neuroscience Nurses·L Logan-Clubb, M Stacy
Oct 9, 1996·JAMA : the Journal of the American Medical Association·L B RussellM C Weinstein
Feb 1, 1996·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·B Weinstock-Guttman, J A Cohen
May 1, 1997·Health Affairs·P FishmanJ Hecht
Jul 17, 1998·Journal of Neurology, Neurosurgery, and Psychiatry·N Koch-HenriksenE Stenager
Nov 17, 1998·Seminars in Neurology·B G Weinshenker
Dec 5, 1998·Multiple Sclerosis : Clinical and Laboratory Research·K Whetten-GoldsteinE D Kulas
Oct 12, 1999·Multiple Sclerosis : Clinical and Laboratory Research·L D JacobsD H Snyder
Sep 30, 2000·PharmacoEconomics·M Kendrick, K I Johnson
Oct 12, 2000·International Journal of Technology Assessment in Health Care·G KobeltB Jönsson
May 30, 2001·Lancet·G ComiUNKNOWN Early Treatment of Multiple Sclerosis Study Group
Mar 8, 2003·BMJ : British Medical Journal·Jim ChilcottUNKNOWN Cost Effectiveness of Multiple Sclerosis Therapies Study Group

❮ Previous
Next ❯

Citations

Mar 13, 2008·Der Nervenarzt·S KernT Ziemssen
May 16, 2009·Advances in Therapy·Jane Castelli-HaleyKenneth P Johnson
May 13, 2006·Journal of Neurology, Neurosurgery, and Psychiatry·G KobeltB Jönsson
Jan 1, 2009·ClinicoEconomics and Outcomes Research : CEOR·Ceri J Phillips, Ioan Humphreys
Oct 28, 2006·PharmacoEconomics·Milton C Weinstein
Aug 25, 2010·Drugs·Jessica SharacRamon Sabes-Figuera
Jul 14, 2012·PharmacoEconomics·Lisa A Prosser
Aug 15, 2009·Vojnosanitetski pregled. Military-medical and pharmaceutical review·Slobodan M JankovićRadosava Vucković
May 3, 2013·Applied Health Economics and Health Policy·Annie HawtonColin Green
Apr 26, 2013·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Carole DembekM R Blasco
Mar 20, 2014·PharmacoEconomics·Shien GuoAnuraag Kansal
Feb 1, 2008·Expert Review of Pharmacoeconomics & Outcomes Research·Trygve Holmoy, Elisabeth Gulowsen Celius
Oct 19, 2010·Expert Review of Pharmacoeconomics & Outcomes Research·Joshua T Cohen
Apr 11, 2013·Expert Review of Pharmacoeconomics & Outcomes Research·Leonardo Koeser, Paul McCrone
Jun 17, 2009·Expert Review of Pharmacoeconomics & Outcomes Research·Kenneth P Johnson, Deborah L Due
Sep 18, 2007·Annals of Neurology·E Ray Dorsey, Robert G Holloway
Nov 3, 2005·Expert Opinion on Emerging Drugs·Rachel FarrellGavin Giovannoni
Aug 24, 2011·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Martin RomeroAristides Duque
Aug 29, 2013·Arquivos de neuro-psiquiatria·Yara Dadalti Fragoso
Jun 5, 2007·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Lisa A Prosser, Eve Wittenberg
Jul 30, 2019·Multiple Sclerosis : Clinical and Laboratory Research·Natalie A SchwehrUNKNOWN BeAMS Study Group
Oct 24, 2018·Multiple Sclerosis : Clinical and Laboratory Research·Hasnat AhmadAndrew J Palmer
Jan 10, 2020·Drugs & Aging·Natalie A SchwehrUNKNOWN BeAMS Study group
Oct 23, 2018·Management Science·Diana M NegoescuDan A Iancu
Sep 8, 2009·Applied Health Economics and Health Policy·Stephanie R EarnshawKenneth Johnson
Jan 22, 2021·Expert Review of Pharmacoeconomics & Outcomes Research·Surachat Ngorsuraches, Nabin Poudel
Jul 9, 2021·Multiple Sclerosis and Related Disorders·Michela TinelliPer Soelberg Sørensen

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.